• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer.

作者信息

Tong Zhichao, Zhao Yubo, Bai Shiyu, Ebner Benedikt, Lienhard Lou, Zhao Yuling, Wang Ziqi, Pan Qi, Guo Pengyu, Bracht Thilo, Sitek Barbara, Gschwend Jürgen E, Xu Wanhai, Nawroth Roman

机构信息

Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.

NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

出版信息

Cancer Commun (Lond). 2024 Jun;44(6):700-704. doi: 10.1002/cac2.12532. Epub 2024 Mar 11.

DOI:10.1002/cac2.12532
PMID:38468431
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11194448/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c6/11194448/9644fe47980c/CAC2-44-700-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c6/11194448/9644fe47980c/CAC2-44-700-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c6/11194448/9644fe47980c/CAC2-44-700-g001.jpg

相似文献

1
The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer.化疗耐药性膀胱癌对CDK4/6抑制的耐药机制及与核糖核苷酸还原酶（RNR）抑制的新型联合治疗
Cancer Commun (Lond). 2024 Jun;44(6):700-704. doi: 10.1002/cac2.12532. Epub 2024 Mar 11.
2
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.Elacestrant（RAD1901）在多种对 CDK4/6 抑制剂耐药的 ER+ 乳腺癌模型中表现出抗肿瘤活性。
Breast Cancer Res. 2019 Dec 18;21(1):146. doi: 10.1186/s13058-019-1230-0.
3
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.对细胞周期蛋白依赖性激酶（CDK）4/6抑制剂的耐药性赋予了乳腺癌细胞对其他CDK抑制剂的交叉耐药性，但对化疗药物没有交叉耐药性。
Breast Cancer. 2021 Jan;28(1):206-215. doi: 10.1007/s12282-020-01150-8. Epub 2020 Aug 28.
4
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂的奇闻：作用机制、耐药性及联合策略
Trends Cancer. 2017 Jan;3(1):39-55. doi: 10.1016/j.trecan.2016.11.006.
5
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.雌激素受体阳性乳腺癌对CDK4/6抑制剂的耐药性
Int J Mol Sci. 2021 Nov 14;22(22):12292. doi: 10.3390/ijms222212292.
6
CDK4 and CDK6 kinases: From basic science to cancer therapy.CDK4 和 CDK6 激酶：从基础科学到癌症治疗。
Science. 2022 Jan 14;375(6577):eabc1495. doi: 10.1126/science.abc1495.
7
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.CDK4/6 抑制敏感性和耐药性的机制。
Cancer Cell. 2020 Apr 13;37(4):514-529. doi: 10.1016/j.ccell.2020.03.010.
8
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.化疗与 CDK4/6 抑制剂：出人意料的组合。
Mol Cancer Ther. 2020 Aug;19(8):1575-1588. doi: 10.1158/1535-7163.MCT-18-1161. Epub 2020 Jun 16.
9
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR/HER2 Breast Cancer.晚期 HR/HER2 乳腺癌患者在接受 CDK4/6 抑制剂和内分泌治疗进展后的实用治疗策略和未来方向。
Clin Breast Cancer. 2020 Feb;20(1):1-11. doi: 10.1016/j.clbc.2019.06.017. Epub 2019 Aug 23.
10
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers.选择性 CDK4/6 抑制剂：生物学结果、敏感性决定因素、耐药机制、联合治疗方法和药效学生物标志物。
Am Soc Clin Oncol Educ Book. 2020 May;40:115-126. doi: 10.1200/EDBK_281085.

引用本文的文献

1
Global research landscape of retinoblastoma biomarkers: a multidisciplinary bibliometric analysis based on multiple databases (2005-2025).视网膜母细胞瘤生物标志物的全球研究格局：基于多个数据库的多学科文献计量分析（2005 - 2025年）
J Cancer Res Clin Oncol. 2025 Aug 15;151(8):231. doi: 10.1007/s00432-025-06279-7.
2
CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制通过RB的核转位引发细胞周期停滞，并诱导多步骤分子反应。
Cell Death Discov. 2024 Oct 26;10(1):453. doi: 10.1038/s41420-024-02218-6.